Form 4: Vera Therapeutics Director Patrick Enright Boosts Stake with Significant Share Purchases

Vera Therapeutics, Inc. Director and 10% owner Patrick G. Enright, through affiliated funds, acquired over 250,000 shares of Class A Common Stock in late June 2025, signaling increased insider confidence.

Summary

• Patrick G. Enright, a Director and 10% owner of Vera Therapeutics, Inc. (VERA), acquired a total of 249,900 shares of Class A Common Stock through affiliated entities on June 23 and June 24, 2025.
• On June 23, 2025, 69,798 shares were purchased at a weighted average price of $20.8683 per share, with prices ranging from $20.43 to $21.05. These shares are held indirectly by Longitude Prime Fund, L.P. (LPF).
• Also on June 23, 2025, an additional 139,595 shares were purchased at a weighted average price of $20.8683 per share, with prices ranging from $20.43 to $21.05. These shares are held indirectly by Longitude Venture Partners IV, L.P (LVPIV).
• On June 24, 2025, 13,536 shares were purchased at a weighted average price of $22.3517 per share, with prices ranging from $21.67 to $22.50. These shares are held indirectly by LPF.
• Additionally, on June 24, 2025, 27,071 shares were purchased at a weighted average price of $22.3517 per share, with prices ranging from $21.67 to $22.50. These shares are held indirectly by LVPIV.
• Following these transactions, the beneficial ownership of Class A Common Stock held indirectly by LPF increased to 1,797,619 shares, and by LVPIV increased to 3,596,593 shares.

Sentiment

Score: 8

Explanation: The significant insider buying by a director and 10% owner indicates strong confidence in the company's future, which is a highly positive signal for investors.

Positives

• A Director and 10% owner, Patrick G. Enright, significantly increased his indirect stake in Vera Therapeutics, Inc., indicating strong insider confidence in the company's future prospects.
• The purchases were made at varying price points, including shares acquired at prices up to $22.50, suggesting a belief in continued value at these levels.
• The total acquisition of 249,900 shares represents a substantial investment by a key insider.

Risks

• The reporting person and associated entities (Longitude Prime Partners, LLC and Longitude Capital Partners IV, LLC) disclaim beneficial ownership of the shares except to the extent of their respective pecuniary interests, which is a standard legal disclaimer but highlights that direct control might be shared or limited.
• The prices reported are weighted averages, meaning some shares were acquired at the higher end of the stated ranges, which could imply a higher cost basis for those specific acquisitions.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider buying, particularly by a director and significant owner, can be interpreted as a positive signal of confidence in the company's prospects within the biotechnology or pharmaceutical industry, suggesting that the insider believes the stock is undervalued or expects positive developments.

Comparison to Industry Standards

• This Form 4 reports standard insider equity purchases. While specific comparable companies or projects are not mentioned, significant insider buying by a director and 10% owner is generally viewed favorably across industries, as it aligns management's interests with shareholders and signals belief in the company's intrinsic value.
• The transaction prices are specific to Vera Therapeutics' stock performance during the transaction dates.

Corporate Governance

Related Party Transactions

• The shares were acquired indirectly by Longitude Prime Fund, L.P. (LPF) and Longitude Venture Partners IV, L.P (LVPIV).
• Patrick G. Enright is a managing member of Longitude Prime Partners, LLC (LPP), the general partner of LPF, and Longitude Capital Partners IV, LLC (LCPIV), the general partner of LVPIV.
• Juliet Tammenoms Bakker is also a managing member of LPP and LCPIV, sharing voting and dispositive power over these securities.
• The reporting person and associated entities disclaim beneficial ownership except to the extent of their pecuniary interests, clarifying the nature of their indirect control.

Stakeholder Impact

• Shareholders: The significant insider buying by a director and 10% owner is generally viewed as a positive signal, potentially increasing investor confidence and demand for the stock.
• Management: The transactions align the interests of a key director and significant shareholder with those of other shareholders, reinforcing commitment to the company's success.

Key Dates

Recommendation

Keywords

Vera Therapeutics, VERA, Insider Trading, Form 4, Stock Purchase, Director, 10% Owner, Patrick G. Enright, Longitude Capital, Equity Acquisition, Biotechnology, Pharmaceuticals